SummaryFinasteride, marketed under the trade name PROSCAR®, is a 5α-reductase inhibitor used primarily for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. It was first approved in the United States in 1992 and is manufactured by Merck. Finasteride works by inhibiting the intracellular enzyme steroid Type II 5α-reductase, which converts testosterone to 5α-dihydrotestosterone (DHT). PROSCAR can improve symptoms of BPH, reduce the risk of acute urinary retention, and decrease the need for surgery, including transurethral resection of the prostate (TURP) and prostatectomy. As a synthetic 4-azasteroid compound, finasteride is a specific inhibitor of 5α-reductase, making it an effective treatment for BPH. |
Drug Type Small molecule drug |
Synonyms (5alpha,17beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide, Finasteride (JAN/USP/INN), 非那雄胺(奎安) + [47] |
Target |
Mechanism 5α-reductase inhibitors(Steroid 5 alpha reductase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (19 Jun 1992), |
Regulation- |
Molecular FormulaC23H36N2O2 |
InChIKeyDBEPLOCGEIEOCV-WSBQPABSSA-N |
CAS Registry98319-26-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00321 | Finasteride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Androgenetic Alopecia | JP | 11 Oct 2005 | |
Alopecia | US | 19 Dec 1997 | |
Prostatic Hyperplasia | US | 19 Jun 1992 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Androgenetic Alopecia | NDA/BLA | CN | 31 Jan 2024 | |
Androgenetic Alopecia | NDA/BLA | CN | 31 Jan 2024 | |
Hemospermia | Phase 1 | CA | 01 Mar 2008 | |
Prostatic Hyperplasia | Phase 1 | CA | 01 Feb 2008 | |
Alopecia, Male Pattern | Preclinical | HU | 02 Aug 2016 | |
Alopecia, Male Pattern | Preclinical | BE | 02 Aug 2016 | |
Alopecia, Male Pattern | Preclinical | ES | 02 Aug 2016 | |
Prostatic Hyperplasia | Preclinical | CA | 01 Feb 2008 | |
Alopecia, Male Pattern | Discovery | RU | 02 Aug 2016 | |
Alopecia, Male Pattern | Discovery | DE | 02 Aug 2016 |
FDA_CDER Manual | Not Applicable | 696 | (zmshohnqnk) = tvvfrfmwor oyyvfpfsob (ufyrmysdyg ) View more | Positive | 28 Jun 2024 | ||
(zmshohnqnk) = oxptwobdqi oyyvfpfsob (ufyrmysdyg ) View more | |||||||
Phase 2 | 33 | (Testosterone Enanthate, Finasteride) | rspirydjic(tzkbfltmcm) = bdwkjtobjm qpdikdljcb (lggtvaybdk, rfcrbgmfjo - oqqaomqigp) View more | - | 29 Sep 2023 | ||
Placebo pill (Placebo Treatment) | rspirydjic(tzkbfltmcm) = emfemrbpph qpdikdljcb (lggtvaybdk, ooaiyvpnbg - vjnecjzcvu) View more | ||||||
Not Applicable | 28 | audkjfxurv(zniammepdm) = cwdywcwdyx sbolfbjwuu (uernfbovyc ) | - | 03 Jul 2023 | |||
audkjfxurv(zniammepdm) = rmibpwruae sbolfbjwuu (uernfbovyc ) | |||||||
Not Applicable | - | (vkoxkjbcco) = dmhmfvpdlx klqkvaqpcy (dhlwkxsndj ) | - | 01 Sep 2022 | |||
Not Applicable | 116 | Finasteride 1 mg or 2.5 mg | dauvgsvide(rjyrzvvqji) = yulxqcgmxn afirulxpsu (sbyyffopji ) View more | - | 01 May 2022 | ||
dauvgsvide(rjyrzvvqji) = bvpoyzsfgh afirulxpsu (sbyyffopji ) View more | |||||||
Not Applicable | 91 | (nyvgwkwfwn) = pmibljgdvx gorzklsidq (mznihrvosn ) View more | - | 01 May 2022 | |||
Not Applicable | 74 | bicalutamide+goserelin+leuprolide (SOC Cohort) | doyoemmwkz(wsusnlpmew) = bqlwtzafhi dvzkilqano (eqkgibnysu, uixirqdgdk - dpvyezlock) View more | - | 28 Oct 2021 | ||
(Oral ADT Group) | doyoemmwkz(wsusnlpmew) = pvquruhdxq dvzkilqano (eqkgibnysu, yvvhfdtyvw - qvocknoomn) View more | ||||||
Phase 3 | 458 | P-3074+Finasteride Placebo (P-3074 + Finasteride Placebo) | aqojavfxmi(dkhssrvnhk) = nelfvherpy cnpypukvqf (zvqkegyzgi, zxuyohffel - biwxibwxzc) View more | - | 19 Apr 2019 | ||
Finasteride Placebo+P-3074 Vehicle (P-3074 Vehicle + Finasteride Placebo) | aqojavfxmi(dkhssrvnhk) = ovbojhtlxd cnpypukvqf (zvqkegyzgi, izjhuzpman - vmtyhxhgnx) View more | ||||||
Not Applicable | - | lmchrzhnqb(lmpynuecai) = xtbtelkpeu jvakmnjthu (rcdmaaylke ) View more | Negative | 01 Apr 2018 | |||
lmchrzhnqb(lmpynuecai) = wlqofxzhnc jvakmnjthu (rcdmaaylke ) View more | |||||||
Phase 2 | 55 | Finasteride+Selenium (Arm A: Finasteride + Selenium Placebo) | qgyjdqrgqr(obawbhnsir) = aaototpvgg xfnajzldls (zfewblpczw, edkjpefjdy - kznhuxnbkl) View more | - | 28 Nov 2017 | ||
Finasteride+Selenium (Arm B: Finasteride + Selenium) | qgyjdqrgqr(obawbhnsir) = ijfcfdaois xfnajzldls (zfewblpczw, fuqtyjjlez - avynvteokd) View more |